Department of Rehabilitation Medicine, Xingtai Central Hospital, Xingtai, China.
Department of Neurology, Xingtai Central Hospital, Xingtai, China.
Medicine (Baltimore). 2024 Apr 5;103(14):e37682. doi: 10.1097/MD.0000000000037682.
This retrospective study aimed to explore the therapeutic potential of Bifidobacterium bifidum supplementation on elderly ischemic stroke patients. We retrospectively analyzed electronic medical records from 153 elderly ischemic stroke patients. Patients were stratified into 2 groups: those receiving B bifidum supplementation (Intervention group, n = 73) and those receiving standard treatment without any additional supplementation (Control group, n = 80). Outcomes were assessed using the National Institutes of Health Stroke Scale (NIHSS), Montreal Cognitive Assessment (MoCA), Self-Rating Depression Scale (SDS), and Self-Rating Anxiety Scale (SAS). Inflammatory markers, immunological indicators, neurotrophic factor, and gut-brain axis (GBA)-related markers were also evaluated at baseline and during 4-week follow-up. Compared to the control group, the intervention group exhibited significant improvements in the NIHSS, MoCA, SDS and SAS scores (P < .001). Enhanced levels of brain-derived neurotrophic factor (BDNF) and reduced levels of NPY were observed in the intervention group. Additionally, inflammatory markers, including IL-6, IL-8, IL-1β, and TNF-α, were significantly reduced in the intervention group, as well as significant increases in immunoglobulin levels (Ig A, Ig G, and Ig M) (P < .001). Besides, lower incidences of diarrhea and constipation were observed in the intervention group (P < .001), while the incidence of abdominal pain was no significant changed. B bifidum supplementation offers promising therapeutic benefits in improving neurological, cognitive, and psychological outcomes in elderly ischemic stroke patients, which may be achieved by regulating the GBA, reducing inflammation and promoting immune function. These findings highlight the importance of integrating gut health strategies in stroke management.
本回顾性研究旨在探讨双歧杆菌补充剂对老年缺血性脑卒中患者的治疗潜力。我们回顾性分析了 153 例老年缺血性脑卒中患者的电子病历。患者分为 2 组：接受双歧杆菌补充剂治疗组（干预组，n=73）和接受标准治疗且不进行任何额外补充的对照组（n=80）。采用国立卫生研究院卒中量表（NIHSS）、蒙特利尔认知评估量表（MoCA）、抑郁自评量表（SDS）和焦虑自评量表（SAS）评估结局。还在基线和 4 周随访时评估了炎症标志物、免疫指标、神经营养因子和肠-脑轴（GBA）相关标志物。与对照组相比，干预组 NIHSS、MoCA、SDS 和 SAS 评分均显著改善（P<0.001）。干预组脑源性神经营养因子（BDNF）水平升高，神经肽 Y（NPY）水平降低。此外，干预组的炎症标志物（包括白细胞介素-6（IL-6）、白细胞介素-8（IL-8）、白细胞介素-1β（IL-1β）和肿瘤坏死因子-α（TNF-α））显著降低，免疫球蛋白水平（IgA、IgG 和 IgM）显著升高（P<0.001）。此外，干预组腹泻和便秘的发生率较低（P<0.001），腹痛的发生率无明显变化。双歧杆菌补充剂为改善老年缺血性脑卒中患者的神经、认知和心理结局提供了有前景的治疗益处，这可能是通过调节 GBA、减少炎症和促进免疫功能实现的。这些发现强调了将肠道健康策略纳入脑卒中管理的重要性。
